

# Physiology and Pathophysiology of Selectins, Integrins, and IgSf Cell Adhesion Molecules Focusing on Inflammation. A Paradigm Model on Infectious Endocarditis

Christos Golias, Anna Batistatou, Georgios Bablekos, Alexandros Charalabopoulos, Dimitrios Peschos, Panagiotis Mitsopoulos & Konstantinos Charalabopoulos

**To cite this article:** Christos Golias, Anna Batistatou, Georgios Bablekos, Alexandros Charalabopoulos, Dimitrios Peschos, Panagiotis Mitsopoulos & Konstantinos Charalabopoulos (2011) Physiology and Pathophysiology of Selectins, Integrins, and IgSf Cell Adhesion Molecules Focusing on Inflammation. A Paradigm Model on Infectious Endocarditis, Cell Communication & Adhesion, 18:3, 19-32, DOI: [10.3109/15419061.2011.606381](https://doi.org/10.3109/15419061.2011.606381)

**To link to this article:** <https://doi.org/10.3109/15419061.2011.606381>



Published online: 05 Sep 2011.



Submit your article to this journal [↗](#)



Article views: 4503



View related articles [↗](#)



Citing articles: 9 View citing articles [↗](#)

# Physiology and Pathophysiology of Selectins, Integrins, and IgSF Cell Adhesion Molecules Focusing on Inflammation. A Paradigm Model on Infectious Endocarditis

CHRISTOS GOLIAS<sup>1,2</sup>, ANNA BATISTATOU<sup>3</sup>, GEORGIOS BABLEKOS<sup>1</sup>,  
ALEXANDROS CHARALABOPOULOS<sup>1</sup>, DIMITRIOS PESCHOS<sup>4</sup>,  
PANAGIOTIS MITSOPOULOS<sup>2</sup> and KONSTANTINOS CHARALABOPOULOS<sup>1</sup>

<sup>1</sup>Department of Physiology, Medical Faculty, Democritus University of Thrace, Alexandroupolis, Greece, <sup>2</sup>Department of Cardiology, Serres State Hospital, Serres, Greece, <sup>3</sup>Department of Pathology, Medical Faculty, University of Ioannina, Ioannina, Greece, <sup>4</sup>Department of Physiology, Medical Faculty, University of Ioannina, Ioannina, Greece

## Abstract

The development of adhesion bonds, either among cells or among cells and components of the extracellular matrix, is a crucial process. These interactions are mediated by some molecules collectively known as adhesion molecules (CAMs). CAMs are ubiquitously expressed proteins playing a central role in controlling cell migration, proliferation, survival, and apoptosis. Besides their key function in physiological maintenance of tissue integrity, CAMs play an eminent role in various pathological processes such as cardiovascular disorders, atherogenesis, atherosclerotic plaque progression and regulation of the inflammatory response. CAMs such as selectins, integrins, and immunoglobulin superfamily take part in interactions between leukocyte and vascular endothelium (leukocyte rolling, arrest, firm adhesion, migration). Experimental data and pathologic observations support the assumption that pathogenic microorganisms attach to vascular endothelial cells or sites of vascular injury initiating intravascular infections. In this review a paradigm focusing on cell adhesion molecules pathophysiology and infective endocarditis development is given.

**Keywords:** cell adhesion molecules, endocarditis, selectins, Immunoglobulin gene superfamily, integrins

## INTRODUCTION

During the last decade, there is enough scientific information in the literature supporting the idea of an important role for cell adhesion molecules in normal human pathophysiological mechanisms as well as in human diseases (Eidelman 1991, Charalabopoulos 2001, Golias 2005, Skubitz 2002, Charalabopoulos 2004). In multicellular organisms primary tissue composition during embryogenesis, tissue growth and their physiologic function as well as their lifetime architectural preservation is thoroughly controlled by a set of reactions either between cells (cell-cell) or between cells and extracellular matter (cell-matrix). The adherence of cells to each other, their extracellular matrices and endothelial surfaces is mediated by a variety of membrane proteins collectively known as cell adhesion molecules (CAMs).

The adhesion molecules are distinguished according to this property into mediators of cell to cell reactions (cell-cell adhesion molecules, CAMs) and mediators of cell to extracellular matrix reactions (cell-substratum adhesion molecules, SAMs). Moreover there are adhesion molecules that can mediate both types of reactions

functioning both as SAMs and CAMs. Thus, adhesion is a vital property of cells. In general it provides a stable environment for cell growth and differentiation and allows cells to migrate. The interaction between cells and their extracellular matrices is also an important factor in the regulation of further protein deposition. Likewise, matrix proteins can influence cellular function thus creating a complex feedback mechanism. CAMs are responsible for those cellular interactions belonging to a complex mechanism which come into play at the receptors on the cell surface. In this mechanism apart from cell adhesion molecules, many other soluble cell mediators like cytokines and components of the tissue matrix like fibronectin, collagen, etc. play a crucial role (Mousa 2008, Pozzi 2003, El Hariry 1997).

Nowadays, a large number of adhesion molecules—more than one hundred—have been identified functioning as SAMs or CAMs or both. Their structure, molecular genetic profile, functional characteristics and biochemical role is fully elucidated to the bibliography. Cell adhesion molecules are substances with a protein character expressed on the cell surface of all tissues. They function as receptors that trigger intracellular pathways and participate in the control of basic vital processes such as embryogenesis, migration, cellular growth and differentiation, cell death, ensuring the interaction of cells with the environment (Golias 2007, Rojas 1999). Specifically, adhesion molecules are membrane receptors that

Received 2 March 2011; accepted 14 July 2011

Address correspondence to Professor K. A. Charalabopoulos, MD, PhD, Department of Physiology, Medical Faculty, Democritus University of Thrace, Dragana University Campus, 68100, Alexandroupolis, Greece. Tel: 003 25510 30513 Fax: 003 25510 30538. E-mail: kcharal@med.duth.gr


mediate several interactions, recognized to play a major role in a variety of normal and pathological phenomena related with traffic and interactions between cells, cell-matrix contact and determining, furthermore, the specificity of cell-cell binding (Rojas 1999, Jaitovich 2004, Charalabopoulos 2002, Batistatou 2006). A variety of recently identified glycoproteins have been implicated in cell-cell interactions that are critical for normal homeostasis, immune surveillance, and vascular wall integrity. These CAMs are known to mediate blood cell (leukocyte, platelet)-endothelial cell interactions that can occur in all segments of the microvasculature under certain physiological (e.g., homeostasis) and pathological (e.g., inflammation, immune responses, cancer) conditions (Kriegelstein 2001, Obene-Abuakwa 2000, Pafilis 2007, Batistatou 2006, Kyzas 2006). From the immunological point of view they are involved in virtually every process of cell interactions, involving thymic selection and antigen priming, antigen recognition and cell activation, cytotoxicity and lymphocyte recirculation (Horvathova 2000). On the other hand, in the development of inflammation, adhesion molecules play an essential role. In general, cytoadhesion molecules play an important role in the pathophysiology of cardiovascular, neoplastic, infectious and skin diseases. Some cardiovascular diseases are associated with pathological impairment of the structure and function of endothelial cells with appearance endothelial dysfunction (Borowska 2006). Particularly, cell adhesion molecules are ubiquitously expressed proteins playing a central role in controlling cell migration, proliferation, survival, and apoptosis. Besides their key function in physiological maintenance of tissue integrity, adhesion molecules play an eminent role in various pathological processes involved in endothelial dysfunction and activation processes. In cardiovascular disorders, cell adhesion molecules are particularly involved in atherogenesis and atherosclerotic plaque progression, myocardial infarction and reperfusion damage, allograft vasculopathy, myocarditis, hypertrophic cardiomyopathy and a minor role in valvular stenosis and cardiomyopathy etc (Jaitovich 2004, Hope 2003).

At present, the main classes of cytoadhesion molecules known are integrins, cadherins, selectins, members of the immunoglobulin gene superfamily (IgSF), and CD44 (Georgolios 2005, Georgolios 2006). Vascular endothelium plays a key role in regulation of the inflammatory response. Adhesion molecules such as selectins, immunoglobulin receptors, integrins, and cadherins as well as connexins expressed on the endothelial cells surface, participate in several interactions. In normal circumstances, they mediate endothelial cell-matrix interactions and regulate vascular permeability. The surface expression of adhesion molecules changes during the process of inflammation. Subsequently, those receptors participate in interactions between leukocytes and activated endothelium surface, in the process of leukocyte activation and their extravasation.

Thus, levels of adhesion molecules may be a diagnostic marker of the systemic endothelial injury (Belohlavkova 1999). In addition to the standard adhesion molecules, a novel approach to the understanding of cell adhesion research is the development of "cell adhesion networks" which include both intrinsic molecules and external regulators that control adhesion function (Zaidel-Bar 2007, Paris 2008, Cirillo 2009). In the present review we present the standard adhesion molecules, their physiology and pathophysiology focusing in inflammation and we give a paradigm model of a complicated, life threatening, difficult and sometimes late diagnosed as well as fluently misdiagnosed infectious disease in the daily clinical practice, like infective endocarditis.

## INTEGRINS

The integrins are transmembrane glycoproteins, heterodimers comprised of  $\alpha$  and  $\beta$  chains that are linked together with disulphide bonds (Figure 1). Integrins are secreted by the epithelial cells as well as from many other types of cells. There are at least 15 different types of  $\alpha$  chain and 9 different types of  $\beta$  chains. Due to this fact a significant number of integrin molecular distribution. The primary classification of integrins was based upon their  $\beta$ -subunit. On the other hand due to the fact that some  $\alpha$ -subunits are linked with more that one type of  $\beta$ -chains it has been introduced a more approachable classification according to the extracellular matrix molecules with which the specific integrin receptors bind. The majority of integrins are members of the  $\beta_1$  subgroup or VLA (Very Late Antigen) and they are expressed from a variety of cellular types. VLA antigens are located to the lymphocytes a few days after they are are triggered from mitogens (Reddy 2003). Moreover,  $\beta_2$  integrin subgroup is consisted of the lymphocyte receptor LFA-1 (Leukocyte Function Associated molecule-1), Mac-1 integrin and p150, 95 integrin all being expressed exclusively at the leukocytes as well as integrin  $\alpha_d\beta_2$  (Reddy 2003, van den Vieren 1995). LFA-1 (CD11a/CD18 or  $\alpha_L\beta_2$ ) is a molecular weight of 275 kDa integrin



**Figure 1.** Basic structure of integrin adhesion molecule.

which is expressed at the vast majority of the white blood cells, implicated in reactions between leukocytes and leukocyte with endothelium. In addition to the inflammatory process LFA-1 integrin is implicated to the adhesion of the cytotoxic T lymphocytes to the “target” cells, to the mixed type lymphocytic reactions and to the lymphocyte proliferation following antigen stimulation (Mc Ever 2007). LFA-1 has been implicated in cases of metastatic lymphomas and it is postulated that it is overexpressed in the small cell type lung carcinoma (Arnaout 2002). Some adhesion molecules such as ICAM-1, ICAM-2 and ICAM-3 of the IgSF are ligands of LFA-1 integrin. Mac-1 integrin (CD11b/CD18 or  $\alpha_M\beta_2$ ) is a molecular weight of 265 kDa protein which is expressed at most of the white blood cell types conducting an important role at the adhesion reactions between leukocytes and leukocyte to endothelium (especially those reactions between neutrophils and endothelial cells). Specifically, Mac-1 is connected to the linkage reactions with the complement (Mc Ever 2007). Ligands for Mac-1 are considered ICAM-1, ICAM-3, fibrinogen, C3bi complement fragment (Arnaout 2002). Integrin p150,95 is a molecular weight 245 kDa protein (Leu M<sub>5</sub> or CD11c/CD18  $\alpha_X\beta_2$ ) which is expressed at most of the white blood cell types at has a role at the cross reactions between leukocytes and leukocyte to endothelium (Hogg 1986). This integrin is implicated at the inflammation and chemotactic process, B-cell activation and CTL mediated cellular destruction. Regarding p150, 95 integrin fibrinogen and C3bi are postulated as its ligands (Pignatelli 1998). The  $\beta_3$  integrin subgroup the so called cytoadhesins, they are expressed mainly at the endothelial cells and the platelets. They consist of a glycoprotein called gpIIb/IIIa and the fibronectin receptor. gpIIb/IIIa platelet integrin is a glycoprotein of a 250 kDa molecular weight (CD41/CD61 or  $\alpha_{IIb}\beta_3$ ) that is expressed with resting platelets and links with fibrinogen. When platelets are activated its role as a gpIIb/IIIa receptor is activated causing a subsequent high affinity relationship to fibronectin and von Willebrand factor leading finally to platelet aggregation (van den Vieren 1995, Mc Ever 2007, Arnaout 2002, Pignatelli 1998, Mc Ever 2009, Bluchbern 1993). Integrin ligands comprise the bacterial and viral proteins, coagulation and fibrinolysis factors complement proteins and cellular anti-receptors, as well as the abovementioned adhesion molecules of the IgSF family ICAM-1, ICAM-2, ICAM-3, VCAM-1 and CD31 (Arnaout 2002, Hogg 1986, Mc Ever 2009) the classical integrin ligands. It is noticeable to mention that although integrins are expressed they do not link with their receptors unless they are activated. Both integrin and their ligand stereochemical configuration are considered significant in order to cross react. From our best of knowledge, there are three integrin activation mechanisms; cellular activation through receptors such as TCR, cytokine activation like MIP-1 $\beta$  and CD31 molecule mediated activation (Mc Kay 1993). Moreover, regulation of integrin – mediated adhesion is achieved by both robust

and highly dynamic adhesions, events occurring at the same time. Therefore interactions between cell adhesion molecule components are transient and it is the dynamic nature of the adhesion site that makes the respective bond both sensitive and responsive to an external stimulus. Over the years a large number of proteins are identified as components of integrin – mediated cell – ECM (extracellular matrix) adhesions. As the adhesive network grows in complexity and connectivity it is obvious that in order robustness and dynamic plasticity to be achieved at the adhesion site most of these interactions can be switched “on” and “off”. Basic switching mechanisms such as the interaction – partner switch, the conformational switch, the tyrosine – phosphorylation switch, the serine/threonine – phosphorylation switch, the phospholipid switch, the Rho – GTPase switch and the cleavage switch, are found in integrin adhesion networks (Zaidel-Bar 2010).

### Integrins and disease

Integrins have been implicated in processes such as inflammation, cellular growth, intercellular adhesion bonds formation and polarization process (Reddy 2003). Additionally, integrins are implicated to scientific fields such as hematology, neurobiology, thrombosis, cancer biology, inflammation, AIDS (Arnaout 2002). Leukocyte Adhesion Deficiency syndrome (LADs) is a disease characterized at the molecular level of a deficit in  $\beta$  subunit of integrins. The patients suffering from this syndrome present remittent bacterial infection sometimes proved life threatening. Integrin secretion is significantly high at the cellular surface of these organisms (Reddy 2003, Anderson 1987). In the literature we find evidence that integrins mediate the adhesive reactions between cells functioning as cell adhesion molecules. Such integrins are  $\alpha_4\beta_1$  and lymphocyte function associated integrin-1 (LFA-1). Moreover, when integrins function as CAMs they provoke cell adhesion of heterotypic character linking preferably with some of the IgSF like ICAM-1, ICAM-2 and VCAM as well as with some members of the selectin family like endothelial leucocyte adhesion molecule-1, ELAM-1 or L-selectin (Elices 1990, Springer 1990, Bechter 1999). Cell adhesion molecules play a key role in the inflammation process and they are worldwide under investigation with much scientific work in clinical and laboratory level. In the inflammation process the complement is activated followed by macrophage activation with the Fc fragment and the complement receptors to produce cytokines such as IL-1 $\beta$  and TNFa, most probably  $\alpha_4\beta_1$  integrin mediated (Elices 1990, Springer 1990, Bechter 1999). Cytokines produce excessive secretion of ICAM-1. In addition with the intervention of  $\alpha_M\beta_2$  integrin complement activating products, chemokines and the increased endothelial adhesiveness accompany neutrophil recruitment and activation. In order for neutrophils to migrate successfully from the vascular space to the site of infection



through the tissues molecules such as platelets have to act synergically mediated by  $\alpha_{IIb}\beta_3$  integrin (gpIIb/IIIa) platelet integrin a very interesting platelet adhesion molecule. This platelet integrin is related with increased prevalence of thrombus formation though directly implicated with thrombotic cerebral stroke (Mc Ever 2009, Bluchbern 1993, Sumpio 2002). During the last decade specific drug functioning against this platelet integrin is used successfully worldwide. In summary, integrins represent a large family of adhesion receptors that are widely expressed and mainly interact with extracellular matrix components. The affinity and the avidity of integrins can be modulated by different mechanisms triggered either from the extracellular milieu or through intracellular signals. Integrins exert an important role as signal-transducing receptors, activating different biochemical pathways. Additionally integrins modulate key intracellular phenomena, including cell activation, proliferation and apoptosis. They are involved in inflammatory, allergic and neoplastic diseases. Their role is also emphasized in organ response to trauma and in skin lesion redevelopment. Knowing integrin molecular basis and understanding their pathophysiological role contribute significantly to the creation of different strategies for the adequate modification of cellular adhesion and therefore the creation of new diagnostic and therapeutic perspectives controlling the pathogenic processes.


## IMMUNOGLOBULIN GENE SUPERFAMILY (IgSF)

IgSF is the most abundant family of cell surface molecules, accounting for 50% of leukocyte surface glycoproteins. Their structure is characterized by repeated domains, similar to those found in immunoglobulins, built from a tightly packed barrel of  $\beta$  strands (Figure 2). By mutation and selection, the Ig domain has evolved to serve many different functions including; receptors for growth factors, receptors for the Fc region of Ig, and as adhesion molecules, which now seems to be a function of the majority (Krieglstein 2001, Holness 1994). Some members of this family that are of relevance to vascular diseases include intercellular cell adhesion molecules-1 and -2 (ICAM-1, ICAM-2), vascular cell adhesion molecule-1 (VCAM-1), platelet-endothelial cell adhesion molecule (PECAM)-1, and the mucosal addressin cell adhesion molecule-1 (MAdCAM-1). Other molecules include neural cell adhesion molecule (NCAM) and carcinoembryonic antigen (CEA). Additionally, at this family nowadays some other molecules that are implicated at the cell recognition process are introduced like major histocompatibility complex antigens (MHC), T-cell receptor, platelet derived growth factor receptor (PDGF), deleted in colon cancer gene product (DCC), and colony stimulating factor-1 receptor (CSF-1). Leukocyte rolling is a prerequisite for eventual firm adherence to blood vessels. However selectin mediated

adhesion of leukocytes does not lead to firm adhesion and transmigration unless members of the IgSF are involved. Additionally, they undergo increased expression in chronic immunological inflammatory processes (Klein 1998, Zimmermann 1992). For endothelial cell-T cell interactions the most important members of this family are ICAM-1, ICAM-2 and VCAM-1, which serve as surface ligands for the LFA-1 and VLA-4 integrins (Pignatelli 1990).

### Intercellular Adhesion Molecule – 1 (ICAM-1 or CD54)

ICAM-1 (CD54) is a transmembrane glycoprotein of 90 kDa molecular weight with five extracellular immunoglobulin simulated sites. It is basally expressed on many cell types, but its expression is regulated on endothelial cells (Dustin 1986), where it exhibits remarkable heterogeneity between vascular beds (Panetsos 1995, Henninger 1997). The most important ligands for ICAM-1 are considered the  $\beta_2$  integrins LFA-1 and Mac1 (CD11B/CD18) that are expressed in leukocytes. Subsequently, ICAM-1 mediates the leukocyte-ICAM-1 presenting cells adherence. Additionally, ICAM-1 adheres with fibrinogen, hyaluronic acid, red blood cells infected with plasmodium falciparum, and CD 43 (sialoforin). Immunohistologically ICAM-1 is detected either as a transmembrane protein or as a soluble form in blood serum. It is expressed at the endothelial and epithelial cells, at the lymphocytes, monocytes, eosinophils, keratinocytes, dendritic cells, ancestral hematopoietic cells, fibroblasts and hepatocytes (Gearing 1992). There are molecules that up regulate ICAM-1 concentrations like some cytokines (TNF- $\alpha$ ; tumor necrosis factor- $\alpha$ , IFN- $\gamma$ ; interferon- $\gamma$ , IL-1; interleukin-1) and other that down regulate like glucocorticoids. ICAM-1 is found in a biologically active form in serum, probably as a result of proteolytic cleavage from the cell surface, being elevated in patients with various inflammatory syndromes such as septic shock, LAD, cancer and transplantation (Rao 2007). ICAM-1 is expressed to the endothelial and epithelial cells, lymphocytes, monocytes, eosinophils, keratinocytes, dendritic cells, ancestral haemopoietic cells, liver cells and fibroblasts. Deregulation of ICAM-1 expression leading to increased levels is triggered by infectious cytokines (tumor necrosis factor- $\alpha$ , TNF- $\alpha$ ; Interferon- $\gamma$ , INF- $\gamma$ ; Interleukin-1, IL-1), while decreased expression is observed when inflammatory factors such as glucocorticoids are induced. The immune cell circulation related function of ICAM-1 is the best studied till today. Inflammatory cytokines increase the expression of ICAM-1 in the vascular endothelial cells and on the other hand activate the leucocytic integrins LFA-1 and Mac-1 at the site of inflammation. Subsequently, this fact leads to leukocytic adherence to the regional endothelium which is considered to be a necessary step for leukocyte migration at the site of inflammation. There is the cellular type of ICAM-1



**Figure 2.** Schematic presentation of the structure of some members of IgSF CAMs family (ICAM-1, ICAM-2, ICAM-3, VCAM-1, PECAM-1).

with a stable linkage to the cellular membrane and the ELISA (enzyme-linked immunospecific assay) detected soluble form of ICAM-1 (sICAM-1). Soluble forms of ICAM-1 have been reported in biological fluids such as blood serum bronchoalveolar lavage and cerebrospinal fluid. In general, increased serum levels of soluble ICAM-1 are related with different inflammatory conditions caused by bacteria, viruses, autoimmune diseases and kinds of neoplasms. Additionally, different levels of ICAM-1 have been monitored at the adult respiratory distress syndrome (ARDS). Corticosteroids that are used

therapeutically at ARDS inhibit the secretion of ICAM-1 and ELAM-1 (endothelial leukocyte adhesion molecule-1) (Cronstein 1992). Several studies have demonstrated that in some cases of sepsaemia soluble forms of ICAM-1 present fluctuations that are related to the levels of some endotoxins, tumor necrosis factor and different types of cytokines (Leone 2003, Mundhekar 2006). Moreover in the literature we find proof for the implication of ICAM-1 and VCAM in glomerular disease as well as the importance of ICAM molecule in the migration of leukocytes to the brain being implicated in cases

of encephalitis and other immunological type disorders of the central nervous system (Wong 2007).

### **Intercellular Adhesion Molecule – 2 (ICAM-2)**

ICAM-2 is a 55kDa molecular weight molecule found in high concentrations at the resting endothelial cells and secreted by most of leukocytes. In contrast to ICAM-1, ICAM-2 expression is not increased on activated endothelial cells and it is not triggered by cytokine activation (Nortamo 1991). It is considered a truncated form of ICAM-1 that is basally expressed on endothelial cells (de Fougerolles 1991). The expression of ICAM-2 is not triggered by cytokines activation. Moreover, it is found in low levels at leukocytes, epithelial cells and generally in latent phase cells while on the other hand it is stimulated by IFN- $\gamma$ , TNF- $\alpha$ , IL-1 and LPL (lipopolisaccharide) (Cartwright 1995, Verhamme 2006).

### **Intercellular Adhesion Molecule – 3 (ICAM-3 or CD50)**

ICAM-3 (CD50) is a glycoprotein of 120kDa molecular weight and is considered a ligand for leukocytic integrins LFA-1 (CD11a/CD18,  $\alpha_L\beta_2$ ). ICAM-3 is constitutively expressed at high levels by all resting leukocytes, such as monocytes, lymphocytes and neutrophils, as well as antigen presenting cells, showing a pattern of expression clearly distinct from those of ICAM-1 and ICAM-2 (Hollness 1995). During the latent status of T-cells ICAM-3 molecule is considered the ligand for LFA-1. It is possible for ICAM-3 to have a very important role in the activation cascade of the immunologic response, the cellular adhesion and signal transduction if we take into account the fact that it causes increased adhesion through the  $\beta_1$  and  $\beta_2$  integrin pathways (Wong 2007, Acevedo 1993). Additionally, it has been postulated that ICAM-3 is related with lymphomas and myelomas considering that the vascular endothelium in such conditions secretes increased amounts of ICAM-3 (Campanero 1993, Dousis-Anagnostopoulou 1993). Soluble forms of ICAM-3 are found in serum as a result of proteolytic cleavage from the cellular surface. In general ICAM molecules comprise as ligands for integrins mediating heterotypic adherence reactions of cell to cell type (CAMs).

### **Vascular Cell Adhesion Molecule-1 (VCAM-1 or CD106)**

VCAM-1 or CD106 is a 90 kDa glycoprotein which exhibits low to negligible expression on unstimulated endothelial cells, can be profoundly upregulated after cytokine challenge. This molecule is expressed on the surface of activated endothelium and a variety of other cell types including bone marrow fibroblasts, tissue macrophages, and dendritic cells. It can be upregulated by inflammatory mediators such as interleukin1 $\beta$  (IL-1 $\beta$ ), IL-4, CD44, tumor necrosis factor- $\alpha$  (TNF $\alpha$ ), and

interferon- $\gamma$  (IFN- $\gamma$ ) (Steeber 2000). VCAM-1 is a ligand for leukocytic integrins  $\alpha_4\beta_1$  (VLA-4) in cells including eosinophils and for  $\alpha_4\beta_7$  integrins at the activated T-cells at the periphery. VCAM molecule is detected at the blood serum using ELISA most probably as a result of proteolytic cleavage.

### **Platelet Endothelial Cell Adhesion Molecule-1 (PECAM-1)**

PECAM-1 also known as CD31 or endoCAM is a 120 kDa molecular weight glycoprotein constitutively expressed on platelets, monocytes and neutrophils and in large amounts on endothelial cells at intercellular junctions and on T-cell subsets (Albelda 1991, Muller 2003, Vaporciyan 1993). PECAM-1 can mediate adhesion through either homophilic or heterophilic interactions (de Lisser 1994). In lower doses it is produced by platelets, monocytes and neutrophils (Muller 2003, Vaporciyan 1993). It is linked either homotypically with itself or heterotypically with integrin  $\alpha_v\beta_3$ . PECAM-1 is highly implicated to the emigration of leukocytes through the vascular endothelium via intercellular junctions (Muller 2003). We detect the molecule in soluble form in blood serum and this PECAM isotype is responsible for transendothelial migration of leukocytes. Furthermore, it is implicated in the cross reactions of CD8 $^+$  and T-cells with the intercellular adhesion site molecules by stimulating the via integrin adhesion process (Arnaout 2002).

### **Mucosal adhesion cell adhesion molecule (MAdCAM-1)**

The mucosal adhesion MAdCAM-1 is a 58 kDa glycoprotein found on HEV (High Endothelial Venules) and mainly expressed on high endothelial venules of Peyer's patches, on venules in small intestinal lamina propria, on the marginal sinus of the spleen, and on high endothelial venules of embryonic lymph nodes (Streete 1988). It is involved in tissue-specific homing of lymphocytes in lymph nodes and mucosal lymphoid tissues (Kriegelstein 2001, Briskin 1993). The molecule is composed of two amino-terminals Ig like regions presenting a very strong bond with ICAM-1 and VCAM-1 molecules which they present a mucine like region ending in an IgA simulating region. Ligands for MAdCAM-1 are  $\alpha_4\beta_7$  integrin and L-Selectin at the leukocyte surface (Buckley 1996).

### **Neural cell adhesion molecule (NCAM)**

Neural cell adhesion molecule (NCAM) is secreted by a large variety of cell type mostly mesenchymal and neural derived ones. NCAM is implicated mostly in cancer process being present in a variety of neural, neuroendocrine, and mesenchymal tumors. Such tumors are Wilm's tumor, pituitary adenomas, pheochromocytoma, and

small cell lung carcinoma. NCAM is considered a ligand for adhesion molecule  $\alpha_4\beta_1$  integrin found in leukocytes (Aoki 1991, Thomson 1991, Molenaar 1998).

### Carcinoembryonic antigen (CEA)

Carcinoembryonic antigen, (CEA) was discovered on 1965 as a 180 kDa cancer embryonic glycoprotein present in the blood serum of patients with large intestine cancer (Gold 1965). It mediates the adhesion of cell to substratum matter (Paxton 1987, Levin 1991).


### Deleted in Colorectal Cancer molecule (DCC)

DCC is a transmembrane polypeptide composed of 1447 aminoacids processing an external fragment with 4 immunoglobulin like regions and 6 fibronectin like type III regions, showing a homologous character towards neural cell adhesion molecule (NCAM) (Fearon 1990). DCC acts as a NCAM stimulating neuritic growth through a specific intracellular signaling process (Pierceall 1994, Figarella-Bronger 1990).

## SELECTINS

Selectins are lectin like binding transmembrane glycoproteins that mediate the initial low-affinity

leukocyte-endothelial cell interaction that is manifested as leukocyte rolling. This transient binding results in further leukocyte activation and subsequent firm adhesion and transendothelial migration of leukocytes (Figure 3) (Krieglstein 2001, Chavakis 2006, Petri 2006, Tailor 2000). With the presence of calcium lectin region binds with carbohydrates e.g Lewis antigen, in neighbouring cells. Specifically, selectins are implicated in heterotypic interactions between blood cells and endothelial cells during leukocyte migration and firm adhesion (Barthel 2007). Their role is manifested during the initial adherence of the circulating leukocytes to the vascular wall that follows their “rolling” as a response to an infective or a carcinogen mechanism. Additionally, as a response to infection mediators, leukocyte gathering is considered to be crucial for the adequate defence of the organism to any kind of injury or infection. Selectins mainly recognise ligands that possess a carbohydrate region structures that have sialyl-Lewis<sup>x</sup> (sLe<sup>x</sup>) antigen. These reactions selectin – carbohydrates are considered as unstable permitting leukocytes to “roll” on vascular endothelium towards blood flow. There are three closely related members of selectin family each expressed on leukocytes (L-selectin), endothelial cells (E-selectin, P-selectin), and platelets (P-selectin) (Barthel 2007). Each member contains a N-terminal C-type lectin domain (carbohydrate recognition domain), followed by



**Figure 3.** The structure of some members of selectin CAMs family (E-Selectin, L-Selectin, P-Selectin).



an epidermal growth factor (EGF)-like motif, varying numbers of short consensus repeats similar to those found in complement – regulatory proteins (CRP), a transmembrane domain, and a short cytoplasmic tail. Studies using chimeric selectins indicate that both the lectin and the EGF domains are directly involved in cell adhesion and may determine the specificity of ligand binding (Tedder 1995).

Contrary to most of the other CAMs selectin role is strictly restricted to the interactions between leukocytes and the vascular endothelium. In general, selectins share an important role in human physiology. In Leukocyte Adhesion Deficiency II syndrome (LAD II), where selectin ligands are absent; there is an inability to recruit neutrophils into sites of inflammation so that they can not fulfil their role as effector cells in the immune system (von Adrian 1993). Soluble circulating forms of the selectins can be detected in plasma, where elevated levels have been reported in serum of animals and patients with inflammatory diseases (Gearing 1993).

### **P-selectin (CD 62P or GMP-140 or PADGEM)**

P-selectin (CD 62P or GMP-140 or PADGEM) has a molecular weight of 140 kDa and it is stored in specific granules that are present in platelets ( $\alpha$ -granules) and endothelial cells (Weibel-Palade bodies) from where it can be rapidly mobilized to the cell surface in response to a variety of inflammatory agents such as thrombin, histamine complement factors, free radicals and cytokines (Tender 1995, van Gils 2009). Cell surface expression of P-selectin is generally short lived (minutes), which makes it an ideal candidate for mediating early leukocyte-endothelial interactions. Ligand for P Selectin is considered the P-selectin glycoprotein ligand-1 (PSGL-1). PSGL-1 undergoes special glycosylation in order to function as a ligand. P-Selectin mediates as well neutrophil as monocyte adherence to stimulated thrombocytes and stimulated endothelial cells. Additionally mediates the *in vitro* captivation of stimulated B cells together with a subpopulation of T cells in the stimulated endothelium. E-selectin (CD62E, ELAM-1), is expressed by cytokine – activated endothelial cells (Fang 2009, Mc Ever 2004).

### **E-selectin**

E-selectin mediates neutrophil, monocyte and some memory T-cell adhesion to vascular endothelium, and may function as a tissue –specific homing receptor for T cell subsets (Tedder 1995). It is broadly expressed within the vasculature at sites of inflammation. Additionally, it is found in arthritic joints, in heart and renal allograft undergoing rejection, and in cutaneous vessels of inflamed skin with psoriasis, contact dermatitis, and delayed type hypersensitivity reactions (Tedder 1995). E-selectin is found in a biologically active form in serum, as a result of proteolytic cleavage from the cell surface (Gearing 1992, Madri 2000). Many ligands for E selectin

have been reported and are expressed by neutrophils, monocytes and lymphocytes such as ESL-1 ligand (E-Selectin ligand-1) (85) and PSGL-1 (P-Selectin Glycoprotein ligand-1) (Mc Ever 2004). Although there is no preformed (storage) pool of E-selectin in endothelial cells, increased cell surface expression can occur in response to transcription-dependent protein synthesis (Fries 1993).

### **L-selectin (CD26L, LECAM-1, LAM-1, gp90<sup>MEL-14</sup>)**

L-selectin (CD26L, LECAM-1, LAM-1, gp90<sup>MEL-14</sup>) is a 74 kDa molecular weight protein constitutively expressed by leukocytes. It is expressed continuously throughout myeloid differentiation, and is expressed mostly by most circulating neutrophils, monocytes and eosinophils. L-selectin mediates leukocyte binding to activated endothelium at inflammatory sites, and lymphocyte binding with integrin receptors mediation to high endothelial venules of peripheral lymph node during lymphocyte homing (Tedder 1995). Through this mechanism the metastatic procedure of tumors to the lymph nodes takes place. The broad expression of L-selectin allows it to play a role in the trafficking of all leukocyte lineages. Primary forms of red cell line progenitors express L-selectin while the mature red cells does not. Ligands for L selectin that are recognised till today include Mad-CAM-1 and other broad spectrum tissues including those of central nervous system. Soluble form of L-selectin is 3 kDa smaller than surface L-selectin and is bioefficient (Walcheck 1996). Elevated levels of L selectin are reported in patients with acquired immunodeficiency syndrome, leukemias and malignant tumors. Decreased levels are reported in patients with ARDS.

Cytokines, bacterial toxins, and oxidants are known to promote the synthesis of E- and P-selectin in endothelial cells. The major ligands for all three selectins are cell surface glycans that possess a specific sialyl-Lewis<sup>x</sup>-type structure (Hallahan 1997), L-selectin may also serve as a ligand for P- and E-selectin (Kriegelstein 2001, von Adrian 1993, Patel 1995).

## **PATHOPHYSIOLOGY OF CAMs – PARADIGM MODEL IN INFECTIVE ENDOCARDITIS**

### **Pathohysiology of CAMs**


The trafficking of leukocytes within the microcirculation is critical for normal immune surveillance of tissues. In the development of inflammation, adhesion molecules play an essential role in the localization of the inflammatory response. At this level, the vascular endothelium, a governing barrier for the exchanges between blood and the tissues, plays an active part in regulation of the transcapillary permeability, control of proliferation of haematopoietic cells and the phases of the inflammatory response (Moussa 2008). The process of leukocyte recruitment is tightly regulated by the

sequential expression and activation of specific adhesion molecules on the surface of leukocytes and endothelial cells (Figure 4). These adhesion molecules mediate distinct steps in the recruitment of leukocytes in the micro-circulation. Selectins mediate leukocyte rolling, whereas glycoproteins belonging to the integrin and immunoglobulin supergene families enable leukocytes to firmly adhere and emigrate in venules. The leukocyte-endothelial cell adhesion that is mediated by these adhesion molecules has been shown to alter the function of endothelial cells in all segments of the vasculature (i.e., in arterioles, capillaries, and venules) (Tailor 2000). In vivo observations of the behaviour of leukocytes in venules has led to a model of leukocyte-endothelial cell interactions that predicts three sequential and coordinated steps for leukocyte recruitment: rolling, firm adhesion (adherence), and emigration of leukocytes finally (Kriegelstein 2001).

In the dormant state, leukocytes and endothelial cells do not interact. Selectin-binding sites are present on leukocytes but dormant endothelial cells do not express selectins. In case of damage or inflammatory processes of the blood vessels due to the action of released cytokines increased expression of adhesion molecules of the integrin, selectin and immunoglobulin groups occurs and subsequently increased adhesion and migration of inflammatory cells across the vascular wall is observed (Golias 2007). Specifically, to establish an adhesive interaction with endothelial cells, circulating leukocytes must, at first, move from the central stream of flowing blood towards the vessel wall. It is now well accepted that endothelial cell activation results in selectin expression and subsequent interaction of selectins and with their ligands mediating thus, the weak (low-affinity) adhesive interactions that are manifested as leukocyte rolling (Kriegelstein 2001, Petri 2006, Calder 2006). Once leukocyte activation is fulfilled leukocyte integrins bind with IgSF glycoproteins such as ICAM-1 and VCAM-1, permitting firm adhesion. Although other CAM

(e.g., VLA-4, VCAM-1, MadCAM-1, and members of the  $\beta_7$  subfamily of integrins) have also been implicated in leukocyte transiently binding (tethering) and rolling their quantitative significance remains unclear. The tethered leukocytes are then exposed to low concentrations of chemo- attractants/inflammatory mediators that result in leukocyte activation and subsequently elicit integrin-Ig-dependent leukocyte adherence, with a simultaneous downregulation (shedding) of L-selectin. Leukocyte activation is also associated with an increased avidity of the integrins, which can be elicited by chemokines, bacterial peptides, platelet activating factor (PAF), and leukotriene B<sub>4</sub> (Petri 2006, Calder 2006). After they have margined, the active cells migrate by diapedesis towards the site of inflammation by creation of chemotactic signals as the adhesion between the cells is insufficient to induce their migration (Mousa 2008). Leukocyte migration is an important mechanism in the pathogenesis of inflammatory diseases, the regulation of hematopoiesis and hemostasis. The transendothelial migration of leukocytes begins with locomotion of adherent leukocytes toward the endothelial cell-cell junctions. Transendothelial migration is mediated by additional IgSF members like PECAM-1 (Kriegelstein 2001). During this process the cell steadily establishes new adhesive contacts at the migration front while reducing adhesive interactions at the tail occur (Eriksson 2000). It is shown that CD11/CD18 (alpha L, M, X/beta 2) integrins have an important role in subsequent steps of leukocyte migration into tissues (Petri 2006).

Apparently, cell adhesion molecules provide the foundation for cell communication, trafficking, and immune surveillance central to host defence. These soluble adhesion molecules (selectins, integrins, CD44, and members of the Ig superfamily), provide a recognition system between leukocytes, endothelial cells and matrix molecules. The activation and increased expression of these adhesion glycoproteins have been attributed to excessive production of cytokines and oxidants (Tailor



**Figure 4.** Schematic presentation of the stages of leukocyte recruitment (leukocyte rolling, arrest, firm adhesion and migration).

2000). Additionally, the adherence phenomena depend on a process that is strictly controlled by the cytokines and enable intervention of cell-cell reactions and cell-protein recognition of the extra-cellular matrix. Cytokines play a key role in control of the expression and/or avidity of membrane receptors for ligands (Mousa 2008). Deregulation of these adhesion and signal transduction pathways can contribute to continued recruitment and persistent leukocyte activation with unresolved inflammation.

### Infective Endocarditis

Experimental data and pathologic observations support the assumption that endothelial cells play a fundamental role in the development of inflammatory processes and various stimuli result in endothelial activation and endothelial leukocyte interactions including adhesion and extravasation. These interactions are mediated by augmented expression of adhesion molecules, such as E-selectin, ICAM-1, and VCAM-1 (Gearing 1992, Leewenberg 1992, Newman 1993, Pigot 1992, Radi 2001). The attachment of pathogenic microorganisms to vascular endothelial cells (EC) or sites of vascular injury is considered a critical initiating event for many types of intravascular infections.

In bacterial endocarditis (BE), the microbial infection is localized on the endocardial surface of the heart and, depending on the bacterial species, may cause an inflammatory reaction that in most cases affects the mural endocardium and the mitral and aortic valves (Bayer 2000). Providing a brief definition, infective endocarditis is a microbial infection of the endothelial surface of the heart. The characteristic lesion, the vegetation, is a variably sized amorphous mass of platelets and fibrin in which abundant microorganisms and moderate inflammatory cells are enmeshed. Acute infective endocarditis is caused typically, although not exclusively, by staphylococcus aureus, whereas the subacute syndrome is more likely to be caused by viridans streptococci, enterococci, coagulase-negative staphylococci, or gram negative coccobacilli. Endothelial activation contributes significantly to the systemic inflammatory response to bacteraemia. Increased expression and release of soluble endothelial markers into the circulation have been demonstrated. Elevated plasma levels of E-selectin have been reported in bacteraemic patients. It has also been proposed that the release of E-selectin is related to the degree of vascular or endothelial injury caused by the sepsis (Cowley 1994, Sessler 1995). Increased plasma and serum levels of VCAM-1 and ICAM-1 have been shown in bacteremic patients. E-selectin as well as ICAM-1 has also been found to be associated with multiple organ dysfunction, septic shock and death (Veltrop 2001). It has been proposed that infection of endothelial cells with *Staphylococcus aureus*, *Streptococcus sanguis*, or *Staphylococcus epidermidis* induces surface expression of intracellular adhesion molecule 1 (ICAM-1) and

vascular cell adhesion molecule 1 (VCAM-1) and monocyte adhesion (Norris 1991).

Several studies have demonstrated that during endocarditis the formation of circulating immune complexes which are identified to contain bacterial components, may contribute directly or indirectly to the stimulation of endothelial cells. Expression of adhesion molecules in vivo can be maintained for several days after stimulation (Cowley 1994, Sessler 1995, Veltrop 2001, Norris 1991, Soderquist 1999, Muller 2000). It has been suggested in the literature that patients with *Staphylococcus aureus* bacteraemia and endocarditis, which represents a sustained endothelial involvement, showed significantly higher E-selectin and VCAM-1 concentrations on admission than those with *Staphylococcus aureus* bacteraemia but without endocarditis which might reflect a more extensive activation of endothelial cells (Soderquist 1999, Marshal 2002, Weber 2003). It is known that in BE intravascular infection with *Staphylococcus aureus*, *Streptococcus sanguis*, or *Staphylococcus epidermidis* can lead to formation of a fibrin clot on the inner surface of the heart and cause heart dysfunction. In addition, the same study was demonstrated that infection of endothelial cells with these three pathogens induces surface expression of ICAM-1 and VCAM-1 as well as monocyte adhesion (Veltrop 2001). Furthermore, by using immunohistochemistry, the CAM expression of endothelial cells on degenerative, mostly calcified heart valves and on heart valves with florid endocarditis was characterized. As expected, the constitutively expressed molecules (ICAM-1, CD34, CD31) were found both on degenerative and on inflamed valves. Furthermore, marked expression of E-selectin and VCAM-1 was found not only on inflamed valves but also on larger portions of the degenerative valves with no morphological evidence of inflammation. This striking finding might help to explain why patients with fibrotic heart valves are susceptible to recurrent endocarditis (Korkmarz 2001). Another perspective was given from a relatively recent study regarding the role of soluble adhesion molecules E- and P- selectin. Specifically, the mean plasma concentrations of P-selectin were elevated in patients with embolic events as compared to both patients without embolic events and control subjects. Similarly, the patients with embolic events had increased plasma levels of E-selectin compared to those without embolic events and the control group (Woodruff 1980). This assumption reflected enhanced platelet activation, which have a direct impact to thrombus generation. Moreover, the increased expression of endothelial activation markers E-selectin and VCAM-1 on degenerative heart, the CAM expression of endothelial cells on degenerative, mostly calcified heart valves and on heart valves with florid endocarditis as well as the constitutively expressed molecules (ICAM-1, CD34, CD31) both on degenerative and on inflamed valves suggest that adhesion molecule mediated leukocyte recruitment or activation of endothelium may constitute a critical role in the



pathogenesis of endocarditis and in the manifestation of its major complications such as thromboembolism (Soderquist 1999, Muller 2000, Koekmaz 2001). However, it remains to be clarified by future studies whether the elevated adhesion molecule levels result from focal release of adhesion molecules at the site of endocardial involvement or from the systemic effects of severe bacteraemic disease. Although, potential clinical value of establishing the diagnosis of endocarditis by measuring serum adhesion molecule concentrations is diminished by the presence of an overlap between the groups of bacteraemic patients with and without endocarditis (Soderquist 1999). CAMs nevertheless constitute relevant diagnostic targets and after additional elaborated studies might be considered as future diagnostic criteria of endocarditis in the future.

## CONCLUSION

Scientific evidence is rapidly accumulating to support the view that leukocyte- and endothelial cell-associated CAM are critical participants in the vascular dysfunction and tissue injury that is associated with a wide variety of inflammatory and cardiovascular diseases. In addition, Advancements in this field of investigation have largely resulted from the marriage of novel immunologic and molecular biological approaches to traditional experimental strategies in cardiovascular physiology. Leukocyte extravasation is a multistep process, mediated by several cell adhesion molecules including selectins (P-, E- and L-), integrins and members of the Ig superfamily (ICAM-1, VCAM-1). These molecules can be targeted for imaging purposes (e.g. to identify atherosclerotic plaques). Furthermore, cell adhesion molecules can serve as drugable targets to prevent leukocyte extravasation where warranted to decrease inflammatory tissue damage (e.g. reperfusion injury). Current techniques involve blocking of binding sites, targeted drug delivery using liposomes and polymeric particles as carriers or imaging of inflammation sites using labeled cells or antibodies. By understanding the cellular and molecular events in leukocyte endothelial cell interaction, strategies on therapies may develop having a specific clinical benefit in the future to overcome tissue damage induced by inflammation process.

**Declaration of interest:** The authors report no declarations of interest.

## REFERENCES

- Eidelman GM and Crossin KL (1991). Cell adhesion molecules: implications for a molecular histology. *Annu Rev Biochem* 60: 155–190.
- Charalabopoulos K, Pignatelli M (2001). Adhesion molecule and cancer. *Arch Hell Med* 18: 16–19.
- Golias Ch, Charalabopoulos A, Peschos D, Maritsi D, Charalabopoulos K, Batistatou A (2005). Adhesion molecules in cancer invasion and metastasis. *Hippokratia* 9:106–114.
- Skubitz AP (2002). Adhesion molecules. *Cancer Treat Res* 107: 305–29.
- Charalabopoulos K, Gogali A, Kostoula OK, Constantopoulos SH (2004). Cadherin superfamily of adhesion molecules in primary lung cancer. *Exp Oncol* 26(4):256–260.
- Mousa SA (2008). Cell adhesion molecules: potential therapeutic & diagnostic implications. *Mol Biotechnol* 38(1):33–40.
- Pozzi A, Zent R (2003). Integrins: sensors of extracellular matrix and modulators of cell function. *Nephron Exp Nephrol* 94(3): e77–84.
- El-Hariry, Pignatelli M (1997). Adhesion molecules: opportunities for modulation and a paradigm for novel therapeutic approaches in cancer. *Expert Opin Investig Drugs* 6:1465–1478.
- Golias C, Tsoutsis E, Matziridis A, Makridis P, Batistatou A, Charalabopoulos K (2007). Review. Leukocyte and endothelial cell adhesion molecules in inflammation focusing on inflammatory heart disease. *In Vivo* 21(5):757–69.
- Rojas AI, Ahmed AR (1999). Adhesion receptors in health and disease. *Crit Rev Oral Biol Med* 10(3):337–58.
- Jaitovich A, Etcheverry GJ (2004). Adhesion molecules. Their role in cardiovascular physiopathology. *Medicina (B Aires)* 64(5):455–462.
- Charalabopoulos K, Binolis J, Karkabounas S (2002). Adhesion molecules in carcinogenesis. *Exp Oncol* 24:249–257.
- Batistatou A, Makrydimas G, Zagoriannakou N, Zagoriannakou P, Nakanishi Y, Agnantis N, Hirohashi S, Charalabopoulos K (2006). Expression of dysadherin and E-cadherin in trophoblastic tissue in normal and abnormal pregnancies. *Placenta* 28(5-6):590–592.
- Kriegelstein C.F., Granger D.N (2001). Adhesion molecules and their role in vascular disease. *American Journal of Hypertension*.
- Ohene-Abuakwa Y, Pignatelli M (2000). Adhesion molecules as diagnostic tools in tumor pathology. *Int J Surg Pathol* 8:191–200.
- Pafilis J, Batistatou A, Iliopoulou A, Tsanou E, Bakogiannis A, Dassopoulos D, Charalabopoulos K (2007). Expression of adhesion molecules during the normal pregnancy. *Cell Tissue Res* 329(1):1–11.
- Batistatou A, Charalabopoulos A, Scopa C, Nakanishi Y, Kappas A, Hirohashi S, Agnantis NJ, Charalabopoulos K (2006). Expression patterns of dysadherin and E-cadherin in lymph node metastases of colorectal carcinoma. *Virchows Archiv* 448(6):763–767.
- Kyzas P, Batistatou A, Stefanou D, Nakanishi Y, Agnantis NJ, Hirohashi S, Charalabopoulos K (2006). Dysadherin expression in head and neck squamous cell carcinoma: association with lymphangiogenesis and prognostic significance. *Am J Surg Pathol* 30:185–193.
- Horvathova M, Ferencik M (2000). The role of adhesion molecules in the immune system. *Bratisl Lek Listy* 101(3):138–145.
- Borowska K, Jedrych B, Czerny K, Zabielski S (2006). The role of integrins in the physiologic and pathogenic processes. *Pol Merkur Lekarski* 21(124):362–366.
- Hope SA, Meredith IT (2003). Cellular adhesion molecules and cardiovascular disease. Part I. Their expression and role in atherogenesis. *Intern Med J* 33(8):380–386.
- Georgiolos A, Batistatou A, Charalabopoulos K (2005). Integrins in head and neck squamous cell carcinoma. A review article of the current literature. *Cell Adhesion Commun* 12–18.



- Georgiolos A, Batistatou A, Charalabopoulos A, Manolopoulos L, Charalabopoulos K (2006). The role of CD44 adhesion molecule in oral cavity cancer. *Exp Oncol* 28(2): 94–98.
- Belohlavkova S, Simak J (1999). Adhesion receptors of the vascular endothelium and their role in acute inflammation. *Cesk Fysiol* 48(2):51
- Zaidel-Bar R, Itzkovitz S, Ma'ayan A, Iyengar R, Geiger B (2007). Functional atlas of the integrin adhesome. *Nat Cell Biol* 9(8):858–867.
- Paris L, Bazzoni G (2008). The protein interaction network of the epithelial junctional complex: a system-level analysis. *Mol Biol Cell* 19(12):5409–5421
- Cirillo N, Prime SS (2009). Desmosomal interactome in keratinocytes: a systems biology approach leading to an understanding of the pathogenesis of skin disease. *CellMol Life Sci* 66(21):3517–3533.
- Reddy KV, Mangale SS (2003). Integrin receptors: the dynamic modulators of endometrial function. *Tissue Cell* 35(4):260–273.
- Van den Vieren M (1995). A novel leukointegrin,  $\alpha_4\beta_2$ , binds preferentially to ICAM-3. *Immunity* 3: 683–690.
- McEver RP, Zhu C (2007). A catch to integrin activation. *Nat Immunol* 8(10):1035–1037.
- Zaidel-Bar R, Geiger B (2010). The switchable integrin adhesome. *J Cell Sci* 123(Pt 9):1385–1388.
- Arnaout MA, Goodman SL, Xiong JP (2002). Coming to grips with integrin binding to ligands. *Curr Opin Cell Biol* 14(5): 641–651.
- Hogg N (1986). The p 150, 95 molecules is a marker of human mononuclear phagocytes: comparison with expression of class II molecules. *Eur J Immunol* 16: 240–248.
- Pignatelli M (1998). Integrins, cadherins, and catenins: molecular cross talk in cancer cells. *J Pathol* 186:1–2.
- McEver RP and Zhu C (2009). Rolling Adhesion. *Annu Rev Cell Dev Biol*.
- Bluchbern BK and Gadek TR1993. Glycoprotein IIb/IIIa antagonists. *Annu Rep Med Chem* 28: 79–87.
- McKay CR, Imhof BA (1993). Cell adhesion in the immune system. *Immunology Today* 14: 99–102.
- Anderson DC, Springer TA (1987). Leukocyte adhesion deficiency: an inherited defect in the Mac-1, LFA-1 and p150, 95 glycoproteins. *Ann Rev Med* 38:175–194.
- Elices MJ, Osborn L, Takada Y (1990). VCAM-1 on activated endothelium interacts with the leukocyte integrin VLA-4 at site distinct from VLA-4/fibronectin binding site. *Cell* 60: 577–584.
- Springer TA (1990). Adhesion receptors on the immune system. *Nature* 346:425–434.
- Bechter OE, Eisterer W, Dirnhöter S (1999). Expression of LFA-1 identifies different prognostic subgroups in patients with advanced follicle center lymphoma (FCL). *Leuk Res* 23(5): 483–488.
- Sumpio BE, Riley JT, Dardik A (2002). Cells in focus: endothelial cell. *Int J Biochem Cell Biol* 34(12):1508–1512.
- Holness C, Simmons DL (1994). Structural motifs for recognition and adhesion in members of the Immunoglobulin superfamily. *J Cell Sci* 107: 2065–2070.
- Klein RM, Breuer R, Mundhenke M, Schwartzkopff B, Strauer BE (1998). Circulating adhesion molecules (cICAM-1, lcVCAM-1) in patients with suspected inflammatory heart muscle disease. *Z Kardiol* 87 (2):84–93.
- Zimmermann G.A, Prescott SM, McIntyre TM (1992). Endothelial cell interactions with granulocytes: tethering and signaling molecules. *Immunol Today* 13(3):93–100.
- Pignatelli M, Durbin H, Bodmer WF (1990). Carcinoembryonic antigen functions as an accessory adhesion molecule mediating colon epithelial cell-collagen interactions. *Proc Natl Acad Sci USA* 87:1541–1545.
- Shimizu Y (1992). Lymphocyte interactions with endothelial cells. *Immunol Today* 13:106–112.
- Dustin M.L, Rothlein R, Bhan A.F, Dinarello C.A, Springer T.A (1986). A natural adherence molecule (ICAM-1): induction by IL-1 and IFN-, tissue distribution, biochemistry, and function. *J Immunol* 137: 245–254.
- Panés J, Perry M.A, Anderson D.C, Manning A, Leone B, Cepinskas G, Rosenbloom C.L, Miyasaka M, Kvietys P.R, Granger D.N (1995). Regional differences in constitutive and induced ICAM-1 expression in vivo. *Am J Physiol* 269: H1955–H1964.
- Henninger D.D, Panés J., Eppihimer M, Russell J., Gerritsen M, Anderson D.C, Granger D.N (1997). Cytokine-induced VCAM-1 and ICAM-1 expression in different organs of the mouse. *J Immunol* 158: 1825–1832.
- Gearing AJH (1992). Soluble forms of vascular adhesion molecules, E-selectin, ICAM-1, and VCAM-1: pathological significance. *Ann NY Acad Sci* 667: 324–331.
- Rao RM, Yang L, Garcia-Cardena G, Lusinskas FW (2007). Endothelial-dependent mechanisms of leukocyte recruitment to the vascular wall. *Circ Res* 101 (3):234–247.
- Cronstein BN, Kimmel SC, Levin RI, Martiniuk F, Weissmann G (1992). A mechanism for the antiinflammatory effects of corticosteroids: the glucocorticoid receptor regulates leukocyte adhesion to endothelial cells and expression of endothelial-leukocyte adhesion molecule 1 and intercellular adhesion molecule 1. *Proc Natl Acad Sci U S A* 89(21): 9991–9995.
- Leone M, Garcin F, Chaabane W, Boutière-Albanèse B, Albanèse J, Dignat-Georges F, Martin C (2003). Activation of adhesion molecules in patients with septic shock. *Ann Fr Anesth Reanim* 22(8):721–729.
- Mundhekar AN, Bullard DC, Kucik DF (2006). Intracellular heterogeneity in adhesiveness of endothelium affects early steps in leukocyte adhesion. *Am J Physiol Cell Physiol* 291(1):C130–137.
- Wong D, Prameya R, Dorovini-Zis K (2007). Adhesion and migration of polymorphonuclear leukocytes across human brain microvessel endothelial cells are differentially regulated by endothelial cell adhesion molecules and modulate monolayer permeability. *J Neuroimmunol* 184 (1-2):136–148.
- Nortamo P, Renkonen R, Li, R, Timonen T, Pieta J, Patarroyo M, Gahmberg C.G (1991). The expression of human intercellular adhesion molecule 2 is refractory to inflammatory cytokines. *Eur J Immunol* 21: 2629–2632.
- De Fougerolles A.R, Stacker S.A, Schwarting R, Springer T.A (1991). Characterization of ICAM-2 and evidence for a third counter-receptor for LFA-1. *J Exp Med* 174: 253–267.
- Cartwright JE, Whitley GS, Johnstone A (1995). The expression and release of adhesion molecules by human endothelial cell lines and their consequent binding of lymphocytes. *Exp Cell Res* 217:329–335.
- Verhamme P, Hoylaerts MF (2006). The pivotal role of the endothelium in haemostasis and thrombosis. *Acta Clin Belg* 61(5):213–219.
- Holness C, Bates PA, Little AJ, Buckley CD, McDowall A, Bossy D, Hogg N, Simmons DL (1995). Analysis of the binding site on ICAM-3 for the leukocyte integrin LFA-1. *J Biol Chem* 270: 877–884.
- Acevedo A, del Pozo MA, Arroyo AG, Sanchez-Mateos P, Gonzalez-Amaro R, Sanchez-Madrid F (1993). Distribution of

- ICAM-3-bearing cells in normal human tissues. Expression of a novel counter-receptor for LFA-1 in epidermal Langerhans cells. *Am J Pathol* 143(3):774–783.
- Campanero MR, del Pozo MA, Arroyo AG, Sanchez-Mateos P, Hernandez-Caselles T, Craig A, Pulido R, Sanchez-Madrid F (1993). ICAM-3 interacts with LFA-1 and regulates the LFA-1/ICAM-1 cell adhesion pathway. *J Cell Biol* 123(4):1007–1016.
- Doussis-Anagnostopoulou I, Kaklamanis L, Cordell J, Jones M, Turley H, Pulford K, Simmons D, Mason D, Gatter K (1993). ICAM-3 expression on endothelium in lymphoid malignancy. *Am J Pathol* 143(4):1040–1043.
- Steeber DA, Tedder TF (2000). Adhesion molecule cascades direct lymphocyte recirculation and leukocyte migration during inflammation. *Immunol Res* 22(2-3):299–317.
- Albelda S.M, Muller W.A, Buck C.A, Newman P.J (1991). Molecular and cellular properties of PECAM-1 (endoCAM/CD31): a novel vascular cell-cell adhesion molecule. *J Cell Biol* 114: 1059–1068.
- Muller WA, Weigl SA, Deng X, Phillips DM (2003). PECAM-1 is required for transendothelial migration of leukocytes. *J Exp Med* 178(2):449–460.
- Vaporciyan A (1993). Involvement of PECAM-1 in neutrophil recruitment in vivo. *Science* 262:1580–1582.
- De Lisser H.M, Newman P.J, Albelda S.M (1994). Molecular and functional aspects of PECAM-1/CD31. *Immunol Today* 15:490–495.
- Streete P.R, Berg E.L, Rouse B.T.N, Bargatze R.F, Butcher E.C (1988). A tissue-specific endothelial cell molecule involved in leukocyte homing. *Nature* 331: 41–46.
- Briskin M.J, McEvoy LM, Butcher EC (1993). MadCAM-1 has homology to immunoglobulin and mucin-like adhesion receptors and to IgA. *Nature* 363:461–464.
- Buckley CD, Doyonnas R, Newport JP, Blystone SD, Brown EJ, Watt SM, Simmons DL (1996). Identification of  $\alpha_5\beta_3$  as a heterotypic ligand for CD31/PECAM-1. *J Cell Sci* 109(Pt2): 436–445.
- Aoki J, Umeda M, Takio K, Titani K, Utsumi H, Sasaki M, Inoue K (1991). Neural cell adhesion molecule mediated contact dependent inhibition of growth of near diploid mouse fibroblast cell line m5S/1m. *J Cell Biol* 115: 1751–1761.
- Thomson JA, Grunert F, Zimmerman W (1991). Carcinoembryonic antigen gene family: molecular biology and clinical perspectives. *J Clin Lab Anal* 5: 344–348.
- Molenaar WM, Muntinghe FL (1998). Expression of neural cell adhesion molecules and neurofilament protein isoforms in skeletal muscle tumors. *Hum Pathol* 29(11): 1290–1293.
- Gold P, Freedman SO (1965). Demonstration of tumor specific antigens in human colonic carcinomata by immunological tolerance and absorption techniques. *J Exp Med* 121: 439–443.
- Paxton RJ, Mooser G, Pandle H (1987). Sequence analysis of carcinoembryonic antigen: Identification of glycosylation sites and homology with the immunoglobulin superfamily. *Proc Natl Acad Sci USA* 84: 920–924.
- Levin LV, Griffin TW (1991). Specific adhesion of carcinoembryonic antigen-bearing colorectal cancer cells to immobilized carcinoembryonic antigen. *Cancer Lett* 60(2): 143–152.
- Fearon ER, Cho KR, Nigro JM, Kern SE, Simons JW, Ruppert JM, Hamilton SR, Preisinger AC, Thomas G, Kinzler KW et al (1990). Identification of a chromosome 18q gene that is altered in colorectal cancers. *Science* 247: 247–256.
- Pierceall WE, Cho KR, Getzenberg RH, Reale MA, Hedrick L, Vogelstein B, Fearon ER (1994). NIH3T3 cells expressing the deleted in colorectal cancer tumor suppressor gene product stimulate neurite outgrowth in rat PC12 pheochromocytoma cells. *J Cell Biol* 124(6): 1017–1027.
- Figarella-Bronger D, Nedelec J, Pellissier JF, Boucrant J, Bianco N, Rougon G (1990). Expression of various isoforms of neural cell adhesive molecules and their highly polysialylated comiter parts in diseased human muscles. *J Neurol Sci* 98(1): 21–36.
- Chavakis T, Orlova V. The role of junctional adhesion molecules in interactions between vascular cells. *Methods Mol Biol* 341:37–50, 2006.
- Petri B, Bixel MG (2006). Molecular events during leukocyte diapedesis. *FEBS J* 273(19):4399–407.
- Taylor A, Granger DN (2000). Role of adhesion molecules in vascular regulation and damage. *Curr Hypertens Rep* 2(1):78–83.
- Barthel SR, Gavino JD, Descheny L, Dimitroff CJ (2007). Targeting selectins and selectin ligands in inflammation and cancer. *Expert Opin Ther Targets* 11(11):1473–91.
- Tedder T. F, Steeber DA, Chen A, Engel P (1995). The selectins: vascular adhesion molecules. *FASEB J* 9:866–873.
- Von Adrian U.H, Berger EM, Ramezani L, Chambers JD, Ochs HD, Harlan JM, Paulson JC, Etzioni A, Arfors KE (1993). In vivo behavior of neutrophils from two patients with distinct inherited LAD syndromes. *J Clin Invest* 91:2893–2897.
- Gearing A.J, Newman W (1993). Circulating adhesion molecules in disease. *Immunol Today* 14: 506–512.
- van Gils JM, Zwaginga JJ, Hordijk PL (2009). Molecular and functional interactions among monocytes, platelets, and endothelial cells and their relevance for cardiovascular diseases. *J Leukoc Biol* 85(2):195–204.
- Fang Y, Wu J, McEver RP, Zhu C (2009). Bending rigidities of cell surface molecules P-selectin and PSGL-1. *J Biomech* 42(3):303–307.
- McEver RP (2004). Interactions of selectins with PSGL-1 and other ligands. *Ernst Schering Res Found Workshop* (44): 137–147.
- Gearing A.J.H, Hemingway I, Pigott R, Hughes J, Rees AJ, Cashman SJ (1992). Soluble forms of vascular adhesion molecules, E-selectin, ICAM-1, and VCAM-1: pathological significance. *Annals NY Acad Sci* 667:324–331.
- Madri JA, Graesser D (2000). Cell migration in the immune system: the evolving inter-related roles of adhesion molecules and proteinases. *Dev Immunol* 7(2-4):103–116.
- Fries J.W, Williams A.J, Atkins R.C, Newman W, Lipscomb M.F, Collins T (1993). Expression of VCAM-1 and E-selectin in an in vivo model of endothelial activation. *Am J Pathol* 143: 725–737.
- Walcheck B, Kahn J, Fisher JM et al (1996). Neutrophil rolling altered by inhibition of L-selectin shedding in vitro. *Nature* 380: 720–723.
- Hallahan DE, Kuchibhotla J, Wyble C (1997). Sialyl Lewis X mimetics attenuate E-selectin-mediated adhesion of leukocytes to irradiated human endothelial cells. *Radiat Res* 147(1):41–47.
- Patel K.D, Moore K.L, Nollert M.U, McEver R.P (1995). Neutrophils use both shared and distinct mechanisms to adhere to selectins under static and flow conditions. *J Clin Invest* 96: 1887–1896.
- Lawrence MB, Springer TA (1991). Leukocytes roll on a selectin at physiologic flow rates: distinction from and prerequisite for adhesion through integrins. *Cell* 65:859–873.
- Calder PC (2006). Polyunsaturated fatty acids and inflammation. *Prostaglandins Leukot Essent Fatty Acids* 75(3):197–202.

- Eriksson E.E, Wer Jr Guo, Thoren P, Lindbom L (2000). Direct observations in vivo on the role of endothelial selectins and alpha(4) integrin in cytokine-induced leukocyte-endothelium interactions in the mouse aorta. *Circ Res* 86: 526–533.
- Gearing AJH, Hemingway I, Pigott R, Hughes J, Rees AJ, Cashman SJ (1992). Soluble forms of vascular adhesion molecules, E-selectin, ICAM-1, and VCAM-1: pathologic significance. *Ann NY Acad Sci* 667:324–331.
- Leewenberg JFM, Smeets EF, Neefjes J Shaffer MA, Cinek T, Jeunhomme TM, Ahern TJ, Buurman WA (1992). E-selectin and intercellular adhesion molecule-1 are released by activated human endothelial cells in vitro. *J Immunol* 77:543–549.
- Newman W, Beall LD, Carson CW, Hunder GG, Graben N, Randhawa ZI, Gopal TV, Wiener-Kronish J, Matthay M (1993). Soluble E-selectin is found in supernatants of activated endothelial cells and is elevated in the serum of patients with septic shock. *J Immunol* 150:644–654.
- Pigott R, Dillon LP, Hemingway IH, Gearing AJH (1992). Soluble forms of E-selectin, ICAM-1 and VCAM-1 are present in the supernatants of cytokine-activated endothelial cells. *Biochem Biophys Res Commun* 187:584–589.
- Radi ZA, Kehrli ME Jr, Ackermann MR (2001). Cell adhesion molecules, leukocyte trafficking, and strategies to reduce leukocyte infiltration. *J Vet Intern Med* 15(6):516–529.
- Bayer A S, Scheld W M (2000). Endocarditis and intravascular infections. In: Mandell G L, Bennett J E, Dolin M., editors. Mandell, Douglas, and Bennett's principals and practices of infectious diseases. 5th ed. Philadelphia, Pa: Churchill Livingstone 857–902.
- Cowley HC, Heney D, Gearing AJH, Hemingway I, Webster NR (1994). Increased circulating adhesion molecule concentrations in patients with systemic inflammatory response syndrome: a prospective cohort study. *Crit Care Med* 22:651–657.
- Sessler CN, Windsor AC, Schwartz M (1995). Circulating ICAM-1 is increased in septic shock. *Am J Respir Crit Care Med* 151:1420–1427.
- Veltrop MH, Thompson J, Beekhuizen H (2001). Monocytes augment bacterial species- and strain-dependent induction of tissue factor activity in bacterium-infected human vascular endothelial cells. *Infect Immun* 69 (5): 2797–2807.
- Norris P, Poston RN, Thomas DS, Thornhill M, Hawk J, Haskard DO (1991). The expression of endothelial leukocyte adhesion molecule-1 (ELAM-1), intercellular adhesion molecule-1 (ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1) in experimental cutaneous inflammation: a comparison of ultraviolet B erythema and delayed hypersensitivity. *J Invest Dermatol* 96:763–770.
- Söderquist B, Sundqvist KG, Vikerfors T (1999). Adhesion molecules (E-selectin, intercellular adhesion molecule-1 (ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1)) in sera from patients with Staphylococcus aureus bacteraemia with or without endocarditis. *Clin Exp Immunol* 118 (3):408–411.
- Muller AM, Cronen C, Kupferwasser LI, Oelert H, Muller KM, Kirkpatrick CJ (2000). Expression of endothelial cell adhesion molecules on heart valves: up-regulation in degeneration as well as acute endocarditis. *J Pathol* 191 (1):54–60.
- Marshall D, Haskard DO (2002). Clinical overview of leukocyte adhesion and migration: where are we now? *Semin Immunol* 14(2):133–140.
- Weber C (2003). Novel mechanistic concepts for the control of leukocyte transmigration: specialization of integrins, chemokines, and junctional molecules. *J Mol Med* 81(1): 4–19.
- Korkmaz S, Ileri M, Hisar I, Yetkin E, Kosar F (2001). Increased levels of soluble adhesion molecules, E-selectin and P-selectin, in patients with infective endocarditis and embolic events. *Eur Heart J* 22(10):811–812.
- Woodruff JF (1980). Viral myocarditis: A review. *Am J Pathol* 101:425.